{"doi":"10.1200/jco.21.01308","title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer","abstract":"PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non–small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.53 to 0.87; P = .00251) and progression-free survival (PFS [blinded independent central review; RECIST v1.1]; stratified HR, 0.52; 95% CI, 0.42 to 0.65; P < .0001), with manageable safety. We report updated, exploratory analyses of survival, approximately 5 years after the last patient was randomly assigned. METHODS Patients with WHO performance status 0 or 1 (any tumor programmed cell death-ligand 1 status) were randomly assigned (2:1) to durvalumab (10 mg/kg intravenously; administered once every 2 weeks for 12 months) or placebo, stratified by age, sex, and smoking history. Time-to-event end point analyses were performed using stratified log-rank tests. Medians and landmark survival rates were estimated using the Kaplan-Meier method. RESULTS Seven hundred and nine of 713 randomly assigned patients received durvalumab (473 of 476) or placebo (236 of 237). As of January 11, 2021 (median follow-up, 34.2 months [all patients]; 61.6 months [censored patients]), updated OS (stratified HR, 0.72; 95% CI, 0.59 to 0.89; median, 47.5 v 29.1 months) and PFS (stratified HR, 0.55; 95% CI, 0.45 to 0.68; median, 16.9 v 5.6 months) remained consistent with the primary analyses. Estimated 5-year rates (95% CI) for durvalumab and placebo were 42.9% (38.2 to 47.4) versus 33.4% (27.3 to 39.6) for OS and 33.1% (28.0 to 38.2) versus 19.0% (13.6 to 25.2) for PFS. CONCLUSION These updated analyses demonstrate robust and sustained OS and durable PFS benefit with durvalumab after chemoradiotherapy. An estimated 42.9% of patients randomly assigned to durvalumab remain alive at 5 years and 33.1% of patients randomly assigned to durvalumab remain alive and free of disease progression, establishing a new benchmark for standard of care in this setting.","journal":"Journal of Clinical Oncology","year":2022,"id":231564,"datarank":7.288733060046679,"base_score":7.1891677384203225,"endowment":7.1891677384203225,"self_citation_contribution":1.0783751607630485,"citation_network_contribution":6.210357899283631,"self_endowment_contribution":1.0783751607630485,"citer_contribution":6.210357899283631,"corpus_percentile":null,"corpus_rank":null,"citation_count":1324,"citer_count":100,"citers_with_citation_signal":100,"citers_with_endowment":100,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9501,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02125461"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":245112,"name":"Corinne Faivre‐Finn","orcid":"0000-0001-5617-9781","position":1,"is_corresponding":false},{"id":33772,"name":"Jhanelle E. Gray","orcid":"0000-0003-1304-7062","position":2,"is_corresponding":false},{"id":14178,"name":"David Vicente","orcid":"0000-0002-6210-090X","position":3,"is_corresponding":false},{"id":595041,"name":"David Planchard","orcid":"0000-0002-1565-8310","position":4,"is_corresponding":false},{"id":227930,"name":"Luis Paz‐Ares","orcid":"0000-0002-1947-3364","position":5,"is_corresponding":false},{"id":616106,"name":"Johan Vansteenkiste","orcid":"0000-0002-6721-2775","position":6,"is_corresponding":false},{"id":33787,"name":"Marina Chiara Garassino","orcid":"0000-0002-3821-5598","position":7,"is_corresponding":false},{"id":33767,"name":"Rina Hui","orcid":"0000-0003-0696-7442","position":8,"is_corresponding":false},{"id":840353,"name":"Xavier Quantin","orcid":"0000-0002-5403-3612","position":9,"is_corresponding":false},{"id":241186,"name":"Andreas Rimner","orcid":"0000-0002-1214-3856","position":10,"is_corresponding":false},{"id":498896,"name":"Yi‐Long Wu","orcid":"0000-0002-3611-0258","position":11,"is_corresponding":false},{"id":616108,"name":"Mustafa Özgüroğlu","orcid":"0000-0002-8417-8628","position":12,"is_corresponding":false},{"id":242799,"name":"Ki Hyeong Lee","orcid":"0000-0002-7830-5950","position":13,"is_corresponding":false},{"id":616109,"name":"Terufumi Kato","orcid":"0000-0002-5853-1424","position":14,"is_corresponding":false},{"id":616110,"name":"Maike de Wit","orcid":"0000-0001-5222-7133","position":15,"is_corresponding":false},{"id":33771,"name":"Takayasu Kurata","orcid":"0000-0003-4123-3567","position":16,"is_corresponding":false},{"id":616107,"name":"Martin Reck","orcid":"0000-0002-5336-9739","position":17,"is_corresponding":false},{"id":53174,"name":"Byoung Chul Cho","orcid":"0000-0002-5562-270X","position":18,"is_corresponding":false},{"id":241188,"name":"Suresh Senan","orcid":"0000-0003-3995-2204","position":19,"is_corresponding":false},{"id":254631,"name":"Jarushka Naidoo","orcid":"0000-0002-3470-8686","position":20,"is_corresponding":false},{"id":840354,"name":"Helen Mann","orcid":null,"position":21,"is_corresponding":false},{"id":616111,"name":"Michael Newton","orcid":"0000-0003-1649-4116","position":22,"is_corresponding":false},{"id":616112,"name":"Piruntha Thiyagarajah","orcid":"0000-0003-4820-3862","position":23,"is_corresponding":false},{"id":1559,"name":"Scott J. Antonia","orcid":null,"position":24,"is_corresponding":false},{"id":1539,"name":"David R. Spigel","orcid":"0000-0003-3215-9465","position":0,"is_corresponding":true}],"reference_count":24,"raw_metadata":null,"created_at":"2026-07-19T00:20:51.245255Z","pmid":"35108059","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}